The European Commission has also approved Celgene's new blood cancer drug pomalidomide for use in combination dexamethasone for adult patients with relapsed and refractory multiple myeloma who ...

NHS patients in England with newly-diagnosed multiple myeloma can be treated with Celgene’s Revlimid as maintenance therapy after a stem cell transplant, after new guidance from NICE.

The results of this report were complemented by another similar initiative, the meta-analysis Evaluate Minimal Residual Disease as an Intermediate Clinical Endpoint for Multiple Myeloma (EVIDENCE ...

During a Case-Based Roundtable® event, Robert Z. Orlowski, MD, PhD, discussed the case of a patient who had progression of ...

Multiple myeloma (MM), which is caused by the transformation ... diagnosed with MM in combination with melphalan (Alkeran; Celgene) and prednisone. This combination, also known as VMP, produced ...

NEW YORK – Bristol Myers Squibb and 2seventy Bio on Monday entered into a merger agreement in which BMS will acquire 2seventy for $286 million, ending the firms' cost-sharing agreement for the ...

Accelerating Myeloma Drug Development: Will Minimal Residual Disease ... Honoraria: Janssen-Cilag (less than $10,000 USD in a single calendar year), Celgene (less than $10,000 USD in a single calendar ...

Sales of Celgene's blockbuster Revlimid, which treats the blood cancer multiple myeloma, rose nearly 18 percent to $2.45 billion, but slightly below analysts' estimates of $2.47 billion.